Everence Capital Management Inc. Has $573,000 Holdings in Glaukos Co. (NYSE:GKOS)

Everence Capital Management Inc. reduced its stake in shares of Glaukos Co. (NYSE:GKOS) by 46.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,820 shares of the medical instruments supplier’s stock after selling 3,280 shares during the quarter. Everence Capital Management Inc.’s holdings in Glaukos were worth $573,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GKOS. Values First Advisors Inc. acquired a new position in shares of Glaukos in the third quarter worth $25,000. Harvest Fund Management Co. Ltd lifted its stake in Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 860 shares during the last quarter. KBC Group NV lifted its stake in shares of Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 201 shares during the last quarter. Brighton Jones LLC acquired a new position in Glaukos during the second quarter worth $208,000. Finally, EWA LLC bought a new position in Glaukos during the third quarter valued at about $209,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Glaukos

In related news, Director Gilbert H. Kliman sold 2,000 shares of Glaukos stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total value of $288,020.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at $4,656,707.36. The trade was a 5.82 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Joseph E. Gilliam sold 2,275 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now owns 102,169 shares in the company, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 17,603 shares of company stock valued at $2,605,678 in the last ninety days. Insiders own 6.40% of the company’s stock.

Glaukos Stock Performance

NYSE:GKOS opened at $151.45 on Friday. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The firm has a 50-day moving average price of $142.09 and a 200 day moving average price of $130.72. The firm has a market capitalization of $8.35 billion, a PE ratio of -50.15 and a beta of 1.03. Glaukos Co. has a 12-month low of $75.90 and a 12-month high of $153.50.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. During the same quarter in the previous year, the firm earned ($0.50) EPS. Glaukos’s quarterly revenue was up 23.9% on a year-over-year basis. Research analysts anticipate that Glaukos Co. will post -1.89 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on GKOS. UBS Group assumed coverage on Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 price objective on the stock. Morgan Stanley lowered shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a research report on Monday, December 2nd. JPMorgan Chase & Co. raised their target price on shares of Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Stifel Nicolaus boosted their target price on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, December 31st. Finally, BTIG Research raised their price target on Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $147.75.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.